🔗 Share this article

Given that the United States undertakes unprecedented changes to its vaccine schedules, an unexpected name has emerged in a surprising turn: Høeg, a US-based sports physician and epidemiologist who first made her name by expressing skepticism about Covid vaccinations throughout the global health crisis and has concentrated on potential fatalities after Covid vaccination in her recent tenure at the Food and Drug Administration.

Scheduled Shifts to Childhood Immunization Schedule

Public health authorities were set to announce radical revisions to the childhood immunization program earlier this month, aligning the US with Denmark’s vaccine program, sources say – a substantial departure that would put the US at odds with much of the world with no evidence for benefit. The planned update has been postponed until the coming year.

Instead of Vinay Prasad, Høeg is set to speak at the meeting. She was just designated interim head of the FDA’s drug evaluation center, the fifth person to head the division this year.

Consolidating Power at the Regulatory Body

The acting appointment may indicate a strengthened alliance between the pharmaceutical and vaccine divisions as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it points to a renewed priority upon rolling back previously authorized vaccines at the FDA.

Høeg has often pushed for halting certain childhood vaccine recommendations in the US to become more like Denmark, a nation with universal health coverage and a population about the population of the state of Wisconsin.

So far comments, she has persisted in emphasizing on vaccines – traditionally the responsibility of Prasad, chief of the FDA’s vaccine center – as opposed to medication approval.

Concerns Over Qualifications

The appointee has no obvious background in pharmaceutical research, regulation or leadership, which has been standard for former leaders of the biologics center. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since March.

“She doesn’t seem to have the necessary background” for running the drug-regulation department, stated Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in managing a large organization. She is not an expert in pharmaceutical oversight.”

Former commissioners of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of drug development”, said a former acting FDA commissioner. “Frankly, she lacks the kind of background that former directors who headed CBER have had.”

The drug center has an immense portfolio at the agency, Woodcock emphasized.

“Many people just focuses on the new drug program, but the off-patent medication office clears a multitude of generic medications. There is also a biologic copycat branch, over-the-counter program and so forth, and all of those have to be managed,” she said. “The area you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a major management aspect to the position, which supervises over 5,000 employees. “It’s a massive administrative position, if you do it right,” she concluded.

Response and Contentious Policies

When asked about concerns about Dr. Høeg's credentials and whether this appointment signifies more teamwork among regulatory chiefs on immunizations, a representative responded that the “concerns rely on flawed assumptions”.

“Her experience matches the functions of her job,” the representative explained, noting the time Høeg spent advising the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a disputed one-day medication authorization process that apparently worried her preceding directors. “By what process are these medications being picked for this fast-track system? Who takes the calls?” Dr. Howard asked. “There is a lot of lack of transparency happening at the regulatory body right now.”

In general, he said, “the Food and Drug Administration seems to be moving towards more relaxed rules of pharmaceuticals, aside from shots.”

Documented History on Immunizations

Regarding immunizations, Høeg has a clearer, if troubling, history, some experts said. She authored a study using unverified volunteer-provided data to assess the frequency of myocarditis after COVID-19 vaccination. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccines are pose a greater threat than they are.

Included in her “policy goals” for the current federal leadership included changing rules for novel immunizations and discontinuing “unnecessary” vaccines, she remarked after the election on a online show. At the agency, Dr. Høeg has reportedly suggested excluding young men from obtaining COVID-19 vaccines.

“She is an all-around ideologue who begins with her preconceived notions and tailors the evidence to accommodate the evidence in a highly deceptive, untruthful manner,” Howard stated.

Taking Control and a “Revenge Tour”

Høeg became part of other contrarians, {like|